

## CURRENT STATUS OF HEPATITIS C VIRUS INFECTION

Fraga Bueno E, Casás Martínez A, Rodríguez Penín I

Pharmacy Department. Complexo Hospitalario Universitario de Ferrol (Spain)

### BACKGROUND AND IMPORTANCE

According to the “Global health sector strategy on viral hepatitis 2016-2021” published by the World Health Organization (WHO), one of the objectives to be achieved **before 2030** is to **detect 90%** of people infected by **Hepatitis C virus (HCV)** and **provide treatment to 80%** of them.

### AIM AND OBJECTIVES

To **describe and analyse** the current situation of **HCV-infected patients treated with direct-acting antivirals (DAAs)** in a second-level hospital.

### MATERIALS AND METHODS

Retrospective observational study: all patients treated with DAAs in 2021



#### Electronical medical history

- Demographic data
- Date and setting of detection of HCV
- Coinfection with HIV and/or HBV
- Viral load
- Degree of fibrosis
- Previous treatments for HCV
- Therapeutic option used
- Tolerance and effectiveness




### RESULTS

- ❖ 37 patients (70% men)
- ❖ Median age: 56 (IQR: 49-65)
- ❖ Median time from diagnosis to treatment: 49 months (IQR: 2-145)
- ❖ Diagnosis: general practitioner (25), care centre for drug addicts (4), other specialties (8)
- ❖ 3 coinfecting with HIV
- ❖ Degree of fibrosis: F0-F1 (19 patients), F2 (5), F3-F4 (12, 6 with cirrhosis)
- ❖ Median viral load: 3,870,000 IU/ml
- ❖ Previously treated: 5 patients (13%)

### TREATMENT

- Sofosbuvir/ velpatasvir 12 weeks
- Glecaprevir/ pibrentasvir 8 weeks
- Ledipasvir/sofosbuvir 8 weeks
- Sofosbuvir/ velpatasvir 24 weeks



- No therapeutic failure
- No adverse events



### CONCLUSIONS

- Most of the patients treated were detected through the **screening programs** currently implemented in the different care settings of our health area, which may allow achieving the objectives of the WHO.
- With these programs an **early detection** of the infection was achieved, which leads to **less liver damage**.
- All our patients were treated according to the **pharmacotherapeutic options** officially recognized as **more cost-effective**.

Abstract N<sup>o</sup>: 4CPS-089



Contact: [eva.fraga.bueno@sergas.es](mailto:eva.fraga.bueno@sergas.es)